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Abstract
Prebiotics are selectively fermented ingredients that allow specific changes in the gastrointestinal microbiota that confer
health benefits to the host. However, the effects of prebiotics on the human gut microbiota are incomplete as most studies
have relied on methods that fail to cover the breadth of the bacterial community. The goal of this research was to use high
throughput multiplex community sequencing of 16S rDNA tags to gain a community wide perspective of the impact of
prebiotic galactooligosaccharide (GOS) on the fecal microbiota of healthy human subjects. Fecal samples from eighteen
healthy adults were previously obtained during a feeding trial in which each subject consumed a GOS-containing product
for twelve weeks, with four increasing dosages (0, 2.5, 5, and 10 gram) of GOS. Multiplex sequencing of the 16S rDNA tags
revealed that GOS induced significant compositional alterations in the fecal microbiota, principally by increasing the
abundance of organisms within the Actinobacteria. Specifically, several distinct lineages of Bifidobacterium were enriched.
Consumption of GOS led to five- to ten-fold increases in bifidobacteria in half of the subjects. Increases in Firmicutes were
also observed, however, these changes were detectable in only a few individuals. The enrichment of bifidobacteria was
generally at the expense of one group of bacteria, the Bacteroides. The responses to GOS and the magnitude of the
response varied between individuals, were reversible, and were in accordance with dosage. The bifidobacteria were the only
bacteria that were consistently and significantly enriched by GOS, although this substrate supported the growth of diverse
colonic bacteria in mono-culture experiments. These results suggest that GOS can be used to enrich bifidobacteria in the
human gastrointestinal tract with remarkable specificity, and that the bifidogenic properties of GOS that occur in vivo are
caused by selective fermentation as well as by competitive interactions within the intestinal environment.
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Introduction
It has become increasingly recognized that the gastrointestinal
microbiota plays a critical role in human health [1,2], affecting
nutrient utilization and adsorption by the host, the development
and maturation of the immune system, and resistance to infections
[3,4,5,6]. Aberrations in the gut microbiota have been linked to
several complex diseases, including inflammatory bowel disease
[4,7,8,9], obesity, atherosclerosis and cardiovascular disease
[10,11,12,13], type 2 diabetes [14], colorectal cancer [15,16,17],
arthritis [18], and allergic diseases [4,19]. Moreover, the discovery
that it is possible to induce changes in the intestinal microbiota by
dietary strategies [20,21] has led to the suggestion that these
aberrations or imbalances can be corrected and host health
improved [22,23].
One strategy by which the composition and metabolic activity
of the intestinal microbiota can be modulated is via the
introduction of prebiotics into the diet. Prebiotics are defined as
‘‘selectively fermented ingredients that allow specific changes, both
in the composition and/or activity in the gastrointestinal
microbiota that confer benefits upon host well-being and health’’
[24]. Several prebiotics are now widely used commercially in
foods, including inulin, fructooligosaccharides (FOS), resistant
starch, and galactooligosaccharides (GOS). There is now convinc-
ing in vivo evidence that shows that prebiotics can promote growth
of bifidobacteria in the intestinal tract of infants and adults
[25,26]. For GOS in particular, 2 to 3 log increases in the number
of bifidobacteria in fecal samples obtained from individual adults
have been reported [27]. However, the human gut microbiota is
composed of hundreds of species [22], and the impact of prebiotics
on other members of the intestinal microbiota, especially those
that remain unculturable, is generally less well understood.
The specificity of prebiotic substrates has been attributed to
their selective fermentation in the intestinal tract by bifidobacteria
and lactobacilli [25]. Indeed, genes encoding for pathways
involved in metabolism of several oligosaccharides have been
reported to be present in species of Bifidobacterium and Lactobacillus
[28,29,30,31,32,33]. Interestingly, however, in mono-culture,
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an energy or carbon source, including species of Clostridium,
Enterococcus, Bacteroides, and Escherichia [25]. In addition, hundreds
of bacterial species colonize the human gastrointestinal tract,
many of which are not culturable, and knowledge about their
ability to utilize prebiotic substrates is currently very restricted.
Until recently, studies on the in vivo specificity of prebiotics have
relied on either cultural enumeration methods that fail to detect
the majority of microbial species present in the human gut
[20,34,35,36] or on molecular methods, such as quantitative real
time (qRT)-PCR or fluorescent in situ hybridization, that are
restricted to selected bacterial groups. Other methods, such as
denaturing gradient gel electrophoresis (DGGE) and terminal-
restriction fragment length polymorphism, can potentially detect
alterations of any member within the bacterial population, but
have a narrow dynamic range and only detect the most dominant
species present. Despite these limitations, several studies have
shown that the prebiotic response was not completely restricted to
bifidobacteria. For example, Tannock and co-workers showed that
FOS increased staining intensities of not only Bifidobacterium
adolescentis but also Collinsella aerofaciens [37]. In a study using mice,
Apajalahti and colleagues reported that inulin induced community
shifts included increases of bifidobacteria and a decrease in
clostridia, but the major changes were observed within previously
unknown taxa [38]. Therefore, although the bifidogenic effect of
most prebiotic carbohydrates is clearly established, knowledge
about the effect on the entire community is still scarce.
Massive parallel sequencing of amplified 16S DNA tags via
pyrosequencing now provides the means to quantify the fecal
microbiota at increased depth and to span the entire microbial
community. Thus, a much more detailed analysis of how
prebiotics affect the microbiota can be achieved using this
technique, and community wide shifts throughout the entire
phylogenetic spectrum of the bacterial population can be
measured. We recently reported that GOS, incorporated into
caramel-like confections, increased the population of bifidobac-
teria when consumed by healthy adults at doses above 5 g per day,
as assessed by cultural techniques, qRT-PCR, and DGGE [27].
However, other changes in the microbiota were less apparent, due
to the limitations of these techniques. The goal of this current
study, therefore, was to gain a more comprehensive perspective of
the impact of GOS on the entire bacterial community in the fecal
samples of these subjects using high throughput multiplex
community sequencing of 16S rDNA tags. We discovered that
GOS was remarkable for its ability to enrich specifically for
bifidobacteria, despite the observation that the substrate is utilized
by other colonic bacteria when assessed in vitro.
Materials and Methods
Experimental design
The study was approved by the Institutional Review Board at
the University of Nebraska (IRB Approval Number:
2009019551EP), and written informed consent was obtained from
all subjects. The details for the study design were previously
described [27]. Briefly, caramel chews were administered to 18
healthy human volunteers during a 16 week period. The first two
weeks were established as the baseline period, followed by four
sequential testing periods during which chews were administered
for three weeks with GOS dosages at levels of 0.0 g, 2.5 g, 5.0 g,
and 10.0 g GOS per day. A final two-week washout period was
performed at the end of the fourth testing period. Fecal samples
were obtained weekly, and DNA was isolated using a method that
includes both an enzymatic and mechanic cell lysis [27].
Analysis of the fecal microbiota by pyrosequencing
Pyrosequencing of 16S rDNA tags was performed from fecal
DNA as described previously [39]. Briefly, the V1-V3 region of the
16S rDNA gene was amplified by PCR from fecal DNA using
primers adapted for the Roche-454 Titanium kit. A mixture (4:1)
of the primers B-8FM
(59-CCTATCCCCTGTGTGCCTTGGCAGTCTCAGA-
GAGTTTGATCMTGGCTCAG-39) and B-8FMBifido
(59-CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGGGTTC-
GATTCTGGCTCAG-39), were used as the forward primers. The
primer A518R
(59-CCATCTCATCCCTGCGTGTCTCCGACTCAGBBBBBBB-
BATTACCGCGGCTGCTGG-39) containing an 8-base barcode
sequence was used as the reverse primer. Sequences were then
assigned to their respective samples via the barcode. The
8FMBifido was used in combination with primer 8FM, as 16S
DNA sequences within the genus Bifidobacterium are not well
amplified by the latter primer [40].
Equal amounts of the PCR products were combined and gel
purified and then sequenced with the 454/Roche A sequencing
primer kit using a Roche Genome Sequencer GS-FLX. Sequences
were binned according to barcodes, using the Ribosomal Database
Project (RDP) Pyrosequencing Pipeline (http://pyro.cme.msu.
edu/) ‘Initial Process’ tool [41]. Default parameters were
established to remove sequences containing any ambiguous
nucleotides, except for the minimum sequences length, which
was set to 300 bp. BioEdit Software was used to trim the quality
approved sequences to 450 bp before submission to the sequence
analyses (see below).
Sequence analyses to characterize microbial populations
Sequences obtained by pyrosequencing were analyzed using
taxonomy-dependent and taxonomy-independent approaches.
First, the Classifier tool of the RDP was applied (with a minimum
bootstrap value of 80%) to obtain a taxonomic assignment of all
sequences. The Classifier approach allowed a fast determination of
the proportions of bacterial groups at different taxonomic levels
(phylum to genus). Alternatively, the sequences were assigned to
Operational Taxonomic Units (OTUs). Accordingly, all sequences
from each subject were individually aligned using the RDP Aligner
web tool, and then clustered using the RDP Complete Linkage
Clustering web tool (with a maximum distance cutoff of 97%;
[41]). The OTU picking was performed on a per subject basis, as
the entire data set from all of the subjects contained too many
sequences for a quality alignment. OTUs that contained less than
three sequences were excluded from the analyses. Using Statistical
Analysis Software (SAS) to perform ANOVA, the OTUs that were
significantly affected by the treatments in each subject were
identified.
Representative sequences from each OTU whose abundance
was significantly influenced by GOS were subjected to taxonomic
classification using SeqMatch, an RDP web tool. From each
statistically significant OTU identified, five random representative
sequences were aligned to form consensus sequences using
SeqMan Software (DNASTAR Lasergene). The consensus
sequences were grouped and aligned according to phylum
(Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, Proteo-
bacteria, and Verrucomicrobia), together with the most closely
related type strains or entry in the NCBI database using Muscle
3.6 [42]. Phylogenetic trees were assembled by neighbor-joining
with 1,000 bootstrap replicates with MEGA 4.0 Software [43].
Using visual analyses and a distance matrix, OTUs were assigned
as sequence clusters with .97% identity, and consensus sequences
Galactooligosaccharides and Intestinal Microbiota
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described above.
Quantification of each OTU in each sample was performed by
BLASTn analysis with a local database including all the quality
controlled sequences generated by pyrosequencing. A BLASTn
algorithm was used with a 97% cutoff (min. length 300 bp) to
quantify each OTU within each sample. The OTUs that were
closely related to Bifidobacterium adolescentis were quantified by
BLASTn using a cutoff of 98% (min. length 300 bp) as clearly
differentiated clusters could be identified that showed overlap with
97%. The quantification of OTUs in all subjects was then verified
to ensure that individual sequences were not being assigned to
different OTUs. In three occasions, OTUs that were initially
identified as distinct had very high sequence similarities, and were
thus merged together as single OTUs.
Determination of community diversity
Two different methods, the generation of rarefaction curves and
Shannon’s index, were applied to determine the diversity of the
fecal microbiota using 16S rDNA sequence data. The DNA
sequences within each sample were aligned and clustered using
RDP web tools Aligner and Complete Linkage Clustering.
Individual cluster files corresponding to each fecal sample were
used to construct Rarefaction curves and determine the Shannon’s
Index.
Statistical analysis
To identify differences in the composition of the fecal
microbiota induced through dietary treatments (0.0 g, 2.5 g,
5.0 g, and 10.0 g GOS) in all eighteen subjects, one-way ANOVA
tests with repeated measures were performed. Samples obtained
during the baseline and washout periods were not included within
the statistical analysis. Post hoc pair-wise comparisons were done
using Tukey’s method. P-values of ,0.05 were considered
significant unless otherwise stated.
In vitro utilization of GOS by bifidobacteria and other
colonic bacteria
A total of 39 strains of bifiodbacteria were screened for their
ability to use GOS as a growth substrate. Included were 19 lab
strains (from ATCC, commercial sources, and the Department of
Food Science Culture Collection) and 20 isolates obtained from
subjects in the previous study [27]. Strains were grown
anaerobically at 37uC in MRS broth containing 2% GOS (GTC
Nutrition, Golden CO). Because the latter material contains 92%
GOS, with the balance as lactose, glucose, and galactose, control
cultures were prepared that contained an equivalent amount of
these sugars (i.e., 0.16% final concentration). In addition, twenty-
two anaerobic bacteria that were mainly of intestinal origin were
also screened for their ability to use GOS as a growth substrate. All
bacteria were obtained from the USDA ARS Culture Collection
(Peoria, IL) and included strains of Bacteroides thetaiotamicron,
Bacteroides distasonis, Bacteroides fragilis, Bacteroides uniformis, Bacteroides
ovatus, Clostridium butyricum, Clostridium histolyticum, Clostridium
bifermentans, Clostridium difficile, Clostridium innocuum, Clostridium
paraputrificum, Clostridium perfringens, Clostridium ramosum, Clostridium
rumen, Clostridium sporogenes, Enterococcus faecalis, Enterococcus faecium,
Enterobacter aerogenes, and Streptococcus salivarius. Bacteria were
initially propagated in Brain Heart Infusion (BHI) or Reinforced
Clostridial Agar (RCA). To assess growth on GOS, cells were
transferred (2%) into a basal medium [5 g/L Peptone No 3
(Becton, Dickinson, and Company), 5.0 g/L Casitone (Becton,
Dickinson, and Company), 0.5 g/L L-Cysteine (Sigma), 40 mL
Salt Solution, 10 mL Hemin (Sigma), 900 mL Vitamin K3 (Sigma),
and 1 g/L Yeast Extract (Becton, Dickinson, and Company)]
containing 1% GOS (GTC Nutrition, Golden, CO). Control
cultures containing 0.08% mono- and disaccharides were
prepared as above.
All cultures were incubated at 37uC in an anaerobic chamber
(Forma Scientific, Marietta, Ohio) containing an atmosphere of
85% nitrogen, 10% hydrogen, and 5% carbon dioxide and
assessed for growth by optical density measurement at 600 nm in a
Beckman Model 640 spectrophotometer. Each experiment was
done in triplicate and the average optical densities were
determined.
Results
The effect of GOS on the fecal microbial communities
A total of 288 fecal samples were included in this study.
Pyrosequencing resulted in a total of 2.3 million sequences. After
quality control analysis (see Methods), an average of 8,200
sequences per sample was obtained. The mean sequence length
was approximately 450 bp. An average of 2,022 OTUs was
identified per subject. To assess the effect of GOS on the bacterial
diversity in fecal samples, rarefaction curves for all eighteen
subjects were generated (data not shown), and Shannon’s diversity
indices were calculated. This analysis revealed that consumption of
GOS did not alter bacterial diversity of the fecal samples
(p,0.0713).
The overall composition of the gut microbiota in the 18
individuals included in this study is in general agreement with that
of previous studies [13]. During the baseline period (no dietary
modulation), the microbiota was dominated by two phyla,
Firmicutes (64%) and Bacteroidetes (28%). Other phyla detected
included Actinobacteria (3%), Verrucomicrobia (1%), and Pro-
teobacteria (1%). Approximately 3% of the sequences remained
unclassified. At the family level, the predominant groups were the
Lachnospiraceae (31%), Ruminococcaceae (18%), Bacteroidaceae
(12%), and Bifidobacteriaceae (2%). The most common genera
included Bacteroides (12.2%), Fecalibacterium (7.7%), Blautia (7.4%),
Ruminococcus (3.7%), Roseburia (2.2%), Bifidobacterium (1.5%), and
Dorea (1.3%).
Sequence proportions determined by pyrosequencing were used
to determine the effect of GOS on the composition of the
gastrointestinal microbiota. The groups that were significantly
affected are shown in Table 1, according to phylum, family, genus
(by RDP Classifier), and OTUs. The control treatment (0.0 g
GOS in confections) had no effect on the fecal microbiota, as the
microbial populations during this period were not significantly
different from those during the baseline and washout periods
(although slight increases in the family Bacteroidaceae and the
genus Bacteroides were detected). In addition, no significant changes
in the fecal microbiota were detected for a dose of 2.5 g GOS. In
contrast, consumption of 5.0 g GOS led to several significant
changes. There were significant increases (p,0.05) in the family
Bifidobacteriaceae and the genus Bifidobacterium, compared to the
control dose. At the species level, the abundance of only one
OTU, corresponding to the species, Fecalibacterium prausnitzii,
increased significantly at this dose. In contrast, significant
decreases in abundance were observed at both the family and
genus levels for Bacteroidaceae (p,0.01) and Bacteroides (p,0.01),
respectively, at the 5.0 g dose compared to the control.
At the 10.0 g GOS dose, additional differences in the
proportions of several phyla (using taxonomy-based analysis) were
observed (Table 1). There was a significant increase in
Actinobacteria compared to the control (p,0.001), as well as
Galactooligosaccharides and Intestinal Microbiota
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with an increase both in the family Bifidobacteriaceae, the genus
Bifidobacterium, and several OTUs related to Bifidobacterium species.
Although there were not significant differences between the 5
gram and 10 gram dose in Bifidobacteriaceae, the genus
Bifidobacterium, and Bifidobacterium species, the amount of bifido-
bacteria at 10 gram GOS was consistently higher than at 5 gram.
In addition, bifidobacteria were significantly increased at 10 gram
GOS when compared to the 2.5 gram dose (Table 1). Collectively,
the abundances of bifidobacteria determined by pyrosequencing
were highly correlated (r=0.7629, p,0.0001) with the cell counts
previously obtained by qRT-PCR [27] (Figure S1). This supports
previous findings that show that our pyrosequencing approach
allows a quantitative determination of bifidobacteria in human
fecal samples.
There were few bacterial taxa other than bifidobacteria that
were influenced by GOS, based on a taxonomy-based analysis
(Table 1). Statistically significant decreases were observed only
within the family Bacteroidaceae (p,0.05) and the genus
Bacteroides (p,0.05) when compared to the control dose of GOS.
In contrast, the OTU-based approach identified two additional
taxa, Coprococcus comes and F. prausnitzii, whose abundances differed
significantly at 5 and 10 g doses. However, no trend was apparent
from these results (Table 1). Although few taxa were identified that
significantly decreased with the administration of GOS when all
18 subjects were assessed collectively, our analysis nonetheless
showed that different bacterial lineages were decreased in
individual subjects. As shown in Figure S2, the changes were
detected in a small number of subjects and occurred primarily
within taxonomically diverse members within the phyla Firmicutes
(Figure S2A) and Bacteroidetes (Figure S2B). Most of these taxa
were reduced by GOS, but no consistent pattern was detected
among subjects. Thus, it appears that although GOS induces a
rather selective increase of different lineages of bifidobacteria,
GOS does not result in a consistent increase of another bacterial
group or a significant decrease of particular bacterial groups.
GOS enhances different lineages of bifidobacteria
A BLASTn analysis revealed that eight OTUs had statistically
significant changes in abundance at the 10 g GOS dose, six of
which were assigned to the genus Bifidobacterium. Three of the
OTUs showed a high similarity (.97%) to described Bifidobacterium
species, B. adolescentis, B. longum, and B. catenulatum (Table 1,
Figure 1A). The other OTUs (Bifidobacterium spp I, II, and III)
showed lower sequence similarities (91–96%) to known Bifidobac-
terium species, and the phylogenetic analysis shown in Figure 1A
revealed that these OTUs belonged to lineages clearly distinct
from known type strains. Interestingly, two of these OTUs
Table 1. Abundance of bacterial taxa affected by GOS consumption in fecal samples of eighteen human subjects as determined
by pyrosequencing of 16S rRNA tags.
Proportion of bacterial taxa expressed in percentage (Mean ± SD)
Baseline
1 0.0 g
2 2.5 g
2 5.0 g
2 10.0 g
2 Washout
1 P value
3
Phylum
Actinobaceria 2.5262.34 2.5863.59 3.6964.33 5.3966.11 7.1968.88 2.0962.51 ,0.0001
Family
Bfidobacteriaceae 1.5662.14 1.6962.65 2.5063.43 4.2765.18 6.1467.08
***11 1.2462.10 ,0.0001
Bacteroidaceae 12.2267.43 15.03610.66 13.2969.24 11.2069.11
** 11.6669.22
** 13.6968.27 0.0030
Genus
Bifidobacterium 1.2861.81 1.4062.20 2.1362.99 3.6164.46 5.2066.18
***11 1.0561.82 0.0002
Bacteroides 12.2267.43 15.03610.66 13.2969.24 11.2069.11
** 11.6669.22
** 13.6968.27 ,0.0001
Species (OTUs)
Bifidobacterium adolescentis 0.3760.56 0.3460.89 0.4660.86 0.8561.09 1.0361.55
* 0.2160.48 0.0101
Bifidobacterium spp I 0.1560.36 0.1860.33 0.2560.55 0.5261.13 0.7761.41
*1 0.1260.25 ,0.0001
Bifidobacterium spp II 0.4660.94 0.6061.53 0.7661.72 1.4162.38 2.0063.45
*1 0.2260.45 ,0.0001
Bifidobacterium spp III 0.6261.21 0.7862.19 0.9862.02 1.8263.30 2.5064.55
*1 0.4060.92 0.0088
Bifidobacterium longum 0.0960.23 0.0960.23 0.1260.32 0.2260.50 0.3360.85
* 0.1560.38 0.0232
Bifidobacterium catenulatum 0.1560.34 0.2760.88 0.5661.38 0.5161.16 0.9162.08
** 0.2860.78 0.0105
Faecalibacterium prausnitzii 3.5262.71 3.2162.26 3.7162.67 4.3763.67
* 3.1661.82{ 3.4262.28 ,0.0001
Coprococcus comes 2.9062.04 2.4061.75 2.1261.24 1.9961.55 1.7861.11
* 2.1561.30 ,0.0001
1Bacteria populations are averages of the two time points of the baseline period and the two time points of the washout 2 period.
2Bacteria populations are averages of all three time points of the feeding periods.
3Bacterial populations during the dietary treatments were compared to eachother with repeated measures ANOVA and Tukey’s post hoc test.
Significantly different to 0.0 g:
*(p,0.05),
**(p,0.01),
***(p,0.001).
Significantly different to 2.5 g:
1(p,0.05),
11(p,0.01).
Significantly different to 5.0 g:
{(p,0.05).
doi:10.1371/journal.pone.0025200.t001
Galactooligosaccharides and Intestinal Microbiota
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25200Figure 1. Characterization of the fecal microbiota in eighteen subjects that consumed increasing doses of GOS by multiplex
pyrosequencing of 16S rDNA tags. A phylogenetic tree that encompasses the phylum Actinobacteria is shown (A). The tree contains
representative sequences of all OTUs detected that were significantly affected by GOS in individual subjects together with sequences of related
entries in the database. The latter includes both type strains of known species and sequences from molecular studies of human fecal samples.
Sequences were aligned using Muscle 3.6 and the trees were constructed using the neighbor-joining algorithm with 1,000 bootstrap replicates in
MEGA 4.0. The sequences from individual subjects are labeled using open black and closed black symbols, and type strains and other sequenced
human strains are indicated by grey symbols. Those OTUs that were not significantly affected in all eighteen subjects were labeled as ‘‘No
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numerically highest response to GOS (Table 1, Figure 1A).
The population shifts induced by GOS vary among
individuals
Although the consumption of GOS at the higherdoses resulted in
compositional shifts within subjects on a collective basis (Figure 1B),
closer examination of samples from individual subjects revealed that
the effect of GOS on the intestinal composition of participants was
subject to considerable variation among individuals (Figure 2).
Indeed, the data showed that there were some individuals that were
essentially unaffected by GOS consumption, whereas other
experienced significant changes. The most substantial alteration
was the increase in the Actinobacteria (at the phylum, family, genus,
and species levels) which was observed in sixteen of the eighteen
subjects after 5.0 g and seventeen of the subjects after 10.0 g of
GOS. At the genus level, in particular, substantial increases were
observed in the abundances of Bifidobacterium, which increased
approximately ten-fold (from 1–4% up to 18–33%) in four subjects
(subjects 2, 4, 11, and 17), and five-fold in seven additional subjects
(subjects 1, 9, 10, 15, 18). Several culturable isolates (NEGOS 1–3)
were obtained from these subjects and were found to associate
within the distinct Bifidobacterium spp. II lineage (Figure 1A),
indicating that this GOS responding linage contains bacteria that
significance’’. Graphs to the right of the trees show the abundance of the OTUs and bacterial groups that were significantly affected by GOS. The
abundances of all of the Bifidobacterium species affected by GOS consumption, for all eighteen subjects, are shown in B. These graphs show mean
proportions of the three individual samples taken during the treatment periods for each subject. Baseline and washout refer to samples taken in
periods where no GOS was consumed. Repeated measures ANOVA in combination with a Tukey’s post-hoc test were performed to indentify
differences between treatment and control periods, where *=p,0.05, **=p,0.01, and ***=p,0.001. Baseline and washout periods were not
included in the statistic analysis.
doi:10.1371/journal.pone.0025200.g001
Figure 2. Bubble plots showing differences in the proportions of bacterial taxa as a percentage of the entire bacteria population
detected during consumption of 5.0 g (A) and 10.0 g (B) when compared to the control period. The size of the bubbles is representative
of the percent difference. Black ovals represent increases in proportions observed during the GOS consumption period; white ovals represent
decreases.
doi:10.1371/journal.pone.0025200.g002
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Bacteroidetes (at the family, genus, and species levels), which
occurred within all of the subjects at some point after 5.0 g of GOS
was consumed (Figure 2). At the genus level, there was a decrease in
the abundance of Bacteroides in 17 subjects after the 5.0 g GOS dose
(all except subject 4), with 14 of those subjects having a further
decrease after consumption of 10.0 g of GOS.
Temporal dynamics of microbial populations in response
to GOS
Analyses of the community profiles provided insight into how
GOS influenced the population dynamics over the entire 16 week
study period. All of the changes induced by GOS were reversible
within one week, and no differences (Student’s t-test, p.0.05)
could be detected in the proportions of the bacterial groups
between the first washout sample and the baseline sample
(Figure 3). The temporal patterns of the three main phyla
(Actinobacteria, Bacteroidetes, and Firmicutes) and two of the
selected genera (Bifidobacterium and Bacteroides) for five representa-
tive subjects showed that these groups were stable in their
temporal response to GOS. For example, levels of Actinobacteria,
Bacteroidetes, and Firmicutes were remarkably stable in fecal
samples at the baseline and washout periods, and their populations
returned to the baseline level within one to two weeks after GOS
consumption was stopped. The same observations were also made
at the genus level for Bifidobacterium and Bacteroides.
In vitro growth of gastrointestinal microbiota cultures on
the prebiotic GOS
As shown above, GOS induces alterations to the human fecal
microbiota that are remarkably specific for bifidobacteria.
However, GOS utilization was observed to be a strain-specific
phenotype, at least based on in vitro growth studies (Table S1). We
also considered whether or not the ability to utilize GOS as a
growth substrate was restricted to bifidobacteria and absent in
other colonic bacteria. Therefore, we tested the ability of twenty-
two strains of bacteria that are associated with the human
intestinal tract to utilize GOS. This was performed by comparing
growth in media containing GOS with growth in basal medium
(i.e., without an additional source of carbohydrate). This
experiment revealed that 6 of the 11 Clostridium strains could
utilize GOS (Figure S3), as indicated by higher final cell densities
compared to growth without carbohydrates. In addition, three of
the six strains of Bacteroides were also significantly enriched when
GOS was present. Significant growth on GOS was not observed,
however, for strains of the genera Enterococcus, Enterobacter,o r
Streptococcus used in this study.
Discussion
We recently reported that consumption of GOS induced
significant bifidogenic shifts in the fecal microbial community of
18 healthy human adults [27]. Daily doses of 5.0 g were generally
necessary before these effects could be observed either by cultural
methods, DGGE, or qRT-PCR. In addition, we also observed that
when the fecal samples from each subject were analyzed
individually via DGGE or qRT-PCR, the bifidogenic response
to GOS occurred consistently in only half of the subjects, whereas
the other subjects were consistent ‘‘non-responders’’ [27]. In this
current study, all 288 samples (18 subjects at 16 weekly time
points) obtained during the previous study were analyzed by
pyrosequencing 16S rDNA tags to obtain a community wide
insight into the effects of GOS on the composition of the human
Figure 3. Temporal dynamics of the human fecal microbiota in response to the consumption of increasing doses of GOS shown in
five human subjects. Graphs on the left show proportions of the three main phyla (Actinobacteria, Firmicutes, and Bacteroidetes) and two genera
(Bifidobacterium and Bacteroides) that were affected in subjects considered as ‘‘responders’’. Graphs on the right show proportions of the same three
phyla and two genera for subjects considered as ‘‘non-responders’’.
doi:10.1371/journal.pone.0025200.g003
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consistent with our previous report, but also provide new insights
regarding how GOS influences the intestinal microbiota. In
addition, the pyrosequencing analysis confirmed the dose-
dependent bifidogenic effect of GOS. As shown in Figure 1B,
the 2.5 g dose of GOS was not sufficient to induce a response,
while 5 and 10 g doses were. In addition, although there was not a
statistically significant difference between 5 and 10 g, there was a
further increase in bifidobacteria in several subjects when the dose
of GOS was increased to 10 g (Figure 1B and 2). Therefore, this
study supports the suggestion made previously that there is in fact
a dose response to GOS [27].
Prebiotics are described, by definition, as being ‘‘selectively
fermented’’ and able to induce changes in the gastrointestinal
microbiota that are ‘‘specific’’ [24]. Several previous studies have
assessed the effect of GOS consumption on the stability and
diversity of the human intestinal microbiota [27,37,44]. However,
the inability to quantify the microbiota beyond the major taxa has
made it difficult to test this definition and to assess the effect of
prebiotics at greater resolution. The results presented here, using
high throughput pyrosequencing, provide a comprehensive, high
resolution analysis of the gut microbiota from individuals during a
course of prebiotic consumption. The pyrosequencing results have
shown, for the first time that the changes that occur during GOS
consumption are remarkably restricted to a small number of
bacterial groups. Indeed, the only bacteria that consistently
increased in abundance in response to GOS feeding were species
of bifidobacteria. Moreover, this increase in bifidobacteria
abundance, to greater than 15% in some individuals, was
associated with a decrease in one primary group of bacteria,
namely the genus Bacteroides (Table 1, Figure 2). Although we also
observed significant decreases in 24 OTUs within the Firmicutes
phylum in several individuals (Figure S2), these differences were
not significant on a subject-wide basis. Thus, we suggest that
bifidobacteria enrichment by GOS occurs at the expense of a
diverse collection of bacteria, including two phyla and many
species. The increase, therefore, was far more specific than the
decrease. Moreover, because an increase in the abundance of
bifidobacteria following GOS consumption might also result in
increased metabolic activity and a lower colonic pH, a broad,
rather than specific inhibitory effect on the colonic microbiota
would likely be expected [45].
Despite the striking selectivity of GOS, in vivo, microbial
fermentation of GOS, in vitro, was much less selective, as several
bacteria associated with a colonic habitat, were able to utilize
GOS as a growth substrate (Figure S3). Clearly, however, as
Gibson and co-workers have noted [25], the substrate preferences
and competitive forces that exist within the gastrointestinal
environment are quite different or absent in pure culture
environments. Our findings suggest that bifidobacteria not only
have the biochemical and physiological wherewithal to ferment
GOS, but are also able to out-compete other members of the
colonic microbiota for such specialized substrates.
Community analysis by pyrosequencing provided average
sequence reads of 450 bp within the 16S rDNA gene (V1–V3
region), which was sufficient for a reliable phylogenetic assignment
to the species level. Our analysis revealed that six different OTUs
that belonged to the genus Bifidobacterium were significantly
enriched through GOS. Interestingly, numerically, the most
significant increase was detected for OTUs Bifidobacterium spp. II
and III (Figure 1A). These two OTUs grouped separately from
other known type strains and had only 95% and 91% homology to
the type strains of B. adolescentis and B. longum, respectively.
Therefore, the organisms represented by these OTUs may be
distinct, as yet un-described species of GOS-responding bifido-
bacteria. Our data indicates that GOS enriches for different
lineages within the genus Bifidobacterium as compared to resistant
starches, which induced the abundance of bacteria that were more
closely related to the type strain of B. adolescentis [39].
As we noted previously, the response to GOS consumption is
subject to considerable individual variation [27], an observation
confirmed by pyrosequencing. Of the 54 OTUs that were affected
by GOS in individual subjects, 46 did not reach significance when
all of the subjects were included in the analysis. In addition, none
of the taxa that were significantly affected by GOS showed a
response in all eighteen subjects. There are several possible
explanations that may account for the highly individual response
to GOS. First, non-responders might simply not harbor strains of
bifidobacteria that are able to utilize GOS. Thus, the presence of
specific GOS-metabolizing strains would confer responder status
on that individual, whereas individuals, for whom GOS strains
were absent, would be non-responders. However, when we
compared the microbiota composition of the baseline samples
between responders and non-responders we could not identify taxa
or OTUs whose abundance was significantly lower in non-
responders (data not shown). Nonetheless, it remains possible that
non-responders might still lack specific strains capable of
metabolizing GOS that are present in the responders. The ability
of bifidobacteria to use GOS as a growth substrate is a strain
specific phenotype (Table S1; [46,47,48]). Thus, the absence of
such strains in some individuals might not be unexpected. In
addition, other factors could also account for inter-subject
variation, including host-specific environmental constraints, such
as lumen pH or the absence of a limiting nutrient that would
restrict the ability of a given bacterial group or species to increase
in number even if a suitable substrate is provided [39,45]. In
addition, host digestive enzymes could, in theory, be secreted in
some individuals that affect the amount of GOS that withstands
digestion and reaches the colon intact. However, there is no
evidence to question the non-digestibility of GOS in humans [49].
Recently, Sonnenburg and co-workers used a two-species
gnotobiotic mouse model with different combinations of Bacteroides
species to show that the impact of a prebiotic carbohydrate (inulin)
on the relative abundance of the microbes could be predicted by
their genetic and functional differences [5]. The authors proposed
that changes in the gut microbiota brought on by dietary strategies
could be inferred based on either genomic or functional knowledge
of members within these populations. They further suggested that
when coupled with microbiome sequence data, diet could
potentially be personalized to optimize microbiota composition
based on an individual’s microbiota. However, the findings
obtained during this study on GOS suggest that it will be difficult
to predict the impact of dietary substrates on the gut microbiota.
Although GOS is fermented by a wide variety of colonic bacteria
in vitro (which obviously possess the genetic and functional
attributes to ferment this substrate), it was mainly the bifidobac-
teria that were consistently and significantly enriched when all of
the subjects were considered. Similar findings were obtained with
different types of resistant starches, which only induced changes in
a small number of taxa in humans although starch is widely
utilized by gut bacteria [39]. We, therefore, argue that it will likely
be impossible to predict the in vivo response of microbial
communities based on metagenome sequence data of the
functional attributes of individual members, without also consid-
ering the ecological and competitive interactions that occur. The
latter are obviously more complex and more challenging to predict
in more diverse communities than the two-species models used by
Sonnenburg and coworkers [5]. To predict the impact of a dietary
Galactooligosaccharides and Intestinal Microbiota
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models that take functional characteristics of the members,
competitive and mutualistic interactions, and substrate preferences
into account. Indeed, the prebiotic, inulin, has consistently been
reported to reduce the numbers of Bacteroides in the human gut
(probably due to a lowering of the pH) [50,51], despite the ability
of some species to ferment this substrate [52]. Therefore, we
suggest that until the competitive interactions that occur in the
human gut are better understood and can be integrated in
predictive models, human feeding trials, such as the one described
in this study, will be necessary to determine the response of dietary
prebiotics on the gut microbiota.
Supporting Information
Figure S1 Correlation of pyrosequencing and qRT-PCR.
Pearson correlation between cell numbers and percent abundance
of bifidobacteria as determined by qRT-PCR and pyrosequencing.
( )
Figure S2 Characterization of the fecal microbiota in
eighteen subjects that consumed increasing doses of
GOS by multiplex pyrosequencing of 16S rDNA tags.
Phylogenetic trees that encompass the phyla, Firmicutes (A) and
Bacteroidetes (B) are shown. The trees contain representative
sequences of all OTUs that were significantly affected by GOS in
individual subjects together with sequences of related entries in the
database (which included both type strains of known species and
sequences from molecular studies of human fecal samples).
Sequences were aligned in Muscle 3.6 and the trees were built
using the neighbor-joining algorithm with 1,000 bootstrap
replicates in MEGA 4.0. Open black, closed black, and grey
symbols were used to label sequences from individual subjects.
OTUs that were not significantly affected in any of the eighteen
subjects were labeled as ‘‘NS’’. Arrows to the right of each cluster
indicate the number of subjects that showed statistical significance
after ANOVA analysis. The direction of the arrow indicates either
a significant increase (q) or significant decrease (Q) for each
subject showing significance for that particular OTU cluster.
(TIF)
Figure S3 Twenty-two anaerobic bacteria of human
gastrointestinal origin were screened in vitro to deter-
mine their ability to utilize GOS. Average optical densities
and standard deviations for each of the strains are shown, with
GOS-grown cultures in shaded bars and control cultures in open
bars. Significant differences were determined by students T-test
and indicated by asterisks, where p,0.05.
(TIF)
Table S1 Growth of bifidobacteria on galactooligosc-
charides.
(DOC)
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